Chapter 23: Administration of systemic anticancer therapies
Skip chapter table of contents and go to main content
Evidence‐based approaches
Rationale
Indications
Intrathecal administration has proved to be of benefit in prophylactic treatment in cases of leukaemias and some lymphomas, where the CNS may provide a sanctuary site for tumour cells not reached during systemic chemotherapy (Wilkes [268]). It can also be used for metastasis to the brain or leptomeninges from solid tumours, lymphoma and leukaemia (Aiello‐Laws and Rutlidge [2]).
